Global Statistics Representing Oligonucleotide Synthesis Market Scenario
Oligonucleotide synthesis is an essential part of genetic research studies, they also have a wide array of applications in research activities and disease diagnosis. Inexpensiveness and easy availability of synthetic DNA and RNA has paved the way for DNA amplification by PCR. Availability of these oligonucleotides have made it possible to sequence whole human genome, this has further unraveled many hidden facts about the genetic constitution, which now helps in understating different genetic and autoimmune disorders. For instance, more than 7000 genetic diseases are newly found.
In the U.S alone, birth defects affect one in every 33 babies and causes 20% of deaths in infants. Moreover, synthetic oligonucleotides applications have increased in last few years, this has fueled the research of several diseases, like detection of cancer, infectious diseases and genetic diseases. Commercialization of oligonucleotides for different therapies is under development. As per Japan patent office, in 2015, around 141 clinical trails were conducted for oligonucleotide therapies, out of which nearly 20 products will be commercialized soon. One of its kind is SPINRAZA, manufactured by BIOGEN, was approved by FDA in 2016 and is used for the treatment of spinal muscular atrophy. After its approval, over 80% of individuals have been treated with SPINRAZA. The success of SPINRAZA exhibits promising future for upcoming oligonucleotides-based therapies yet to be commercialized.
Global oligonucleotide synthesis market is expected to reach USD 8,200 million in 2026 at a CAGR of 14.2% during the forecast period of 2019–2026.
For a better understanding of the global oligonucleotide synthesis market, we have segmented the market by product type, application and end user.
By product type, the market is segmented into synthesized oligonucleotide, reagents and equipment. Synthesized oligonucleotides segment is leading the global oligonucleotide synthesis market.
Applications of oligonucleotides in drug manufacturing are becoming mainstream, pharmaceutical companies are using them for different indications such as cancer, neurodegenerative, cardiovascular and rare diseases. In 2016, FDA approved eteplirsen, which is a self-splicing oligonucleotide used in the restoration of function caused by muscular dystrophies. Recently in 2018, ‘Dynacare’ a French startup company has launched USD 55 million worth of antisense oligonucleotide drug for the treatment of rare genetic muscle diseases. With every new product launch the application segment is covering a wide range of indications, creating foundation for a promising market scenario.
Global oligonucleotide synthesis market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is expected to hold the largest market share during the forecast period following the increasing investments in research and development in the region. The U.S is leading the oligonucleotide synthesis market in the region. For instance, approximately USD 2 billion funding bill was passed for the NIH and USD 300 million funding for NCI in 2019, American Cancer Society Cancer Action Network Organization. These investments will accelerate the fight against cancer and will help in developing new effective ways for the treatment of the disease. Moreover, around USD 37 million has been spent to support CDC’s cancer programs.
Canada is second leading oligonucleotide synthesis market in the region. This can be attributed to the rowing presence of genetic companies and increasing investments in research and development.
Recently, around USD 2.25 million are invested by Canadian Ovarian Cancer Research to develop better experimental models. Moreover, Editas Medicine, Intellia Therapeutics and Sangamo Therapeutics are some of the prominent players involved in gene editing activities.
Europe is the second leading oligonucleotide synthesis market following the growing demand of personalized data and increasing government support in the region. Many countries have also started genetic tests for autistic people in Europe. For instance, approximately 700,000 people are suffering from autism in the UK, National Autistic Society. Moreover, the United Kingdom and France are planning to build a sequencing facility, create databases and integrate the results of genetic testing into standard healthcare. Currently, 13 centers in the U.K. have started offering whole-genome sequencing to cancer patients and autistic patients. Apart from this, some of the eminent gene research companies are also supporting the overall growth of the market.
Some of the key players in the global oligonucleotide synthesis market are Agilent Technologies, Inc. (U.S.), ATDBio Ltd. (UK), TriLink BioTechnologies, LLC (U.S.), Thermo Fisher Scientific (U.S.), Nitto Denko Corporation (Japan), Merck KGaA (Germany), LGC Biosearch Technologie (UK), Integrated DNA Technologies, Inc.(U.S.), GenScript (U.S.), GE Healthcare (U.S.), Eurogentec (Belgium), and Eurofins (Luxembourg).
Our Report Covers
Oligonucleotide Synthesis Market Segmentation
By Product Type
By End User